Full Text View
Tabular View
No Study Results Posted
Related Studies
Study of RSD1235 to Evaluate Safety in Patients With Atrial Fibrillation (ACT 4)
This study has been completed.
Study NCT00281554   Information provided by Astellas Pharma Inc
First Received: January 24, 2006   Last Updated: April 1, 2008   History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study
About Study Results Reporting on ClinicalTrials.gov
  Study Status: This study has been completed.
  Study Completion Date: January 2007
  Primary Completion Date: January 2007 (Final data collection date for primary outcome measure)
No publications provided by Astellas Pharma Inc

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Stiell IG, Dickinson G, Butterfield NN, Clement CM, Perry JJ, Vaillancourt C, Calder LA. Vernakalant hydrochloride: A NovelAtrial-selective agent for the cardioversionof recent-onset atrial fibrillation in the emergency department. Acad Emerg Med. 2010 Nov;17(11):1175-82.
Stiell IG, Roos JS, Kavanagh KM, Dickinson G. A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm. Am Heart J. 2010 Jun;159(6):1095-101.




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services